Home > Publications database > Identifying colorectal cancer-specific vulnerabilities in the Wnt-driven long non-coding transcriptome. > print

001     294580
005     20250307144935.0
024 7 _ |a 10.1136/gutjnl-2024-332752
|2 doi
024 7 _ |a pmid:39562049
|2 pmid
024 7 _ |a 0017-5749
|2 ISSN
024 7 _ |a 1468-3288
|2 ISSN
037 _ _ |a DKFZ-2024-02355
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Schwarzmueller, Laura J
|b 0
245 _ _ |a Identifying colorectal cancer-specific vulnerabilities in the Wnt-driven long non-coding transcriptome.
260 _ _ |a London
|c 2025
|b BMJ Publishing Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1741355331_14976
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2025 Mar 6;74(4):571-585
520 _ _ |a Aberrant Wnt pathway activation is a key driver of colorectal cancer (CRC) and is essential to sustain tumour growth and progression. Although the downstream protein-coding target genes of the Wnt cascade are well known, the long non-coding transcriptome has not yet been fully resolved.In this study, we aim to comprehensively reveal the Wnt-regulated long non-coding transcriptome and exploit essential molecules as novel therapeutic targets.We used global run-on sequencing to define β-catenin-regulated long non-coding RNAs (lncRNAs) in CRC. CRISPRi dropout screens were subsequently used to establish the functional relevance of a subset of these lncRNAs for long-term expansion of CRC.We uncovered that LINC02418 is essential for cancer cell clonogenic outgrowth. Mechanistically, LINC02418 regulates MYC expression levels to promote CRC stem cell functionality and prevent terminal differentiation. Furthermore, we developed effective small interfering RNA (siRNA)-based therapeutics to target LINC02418 RNA in vivo.We propose that cancer-specific Wnt-regulated lncRNAs provide novel therapeutic opportunities to interfere with the Wnt pathway, which has so far defied effective pharmacological inhibition.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a colorectal cancer
|2 Other
700 1 _ |a Adam, Ronja S
|b 1
700 1 _ |a Moreno, Leandro F
|b 2
700 1 _ |a Nijman, Lisanne E
|b 3
700 1 _ |a Logiantara, Adrian
|b 4
700 1 _ |a Eleonora, Steven
|b 5
700 1 _ |a Bril, Oscar
|b 6
700 1 _ |a Vromans, Sophie
|b 7
700 1 _ |a de Groot, Nina E
|b 8
700 1 _ |a Giugliano, Francesca Paola
|b 9
700 1 _ |a Stepanova, Ekaterina
|0 P:(DE-He78)dc4f734225935c3650fde7619c82ed92
|b 10
700 1 _ |a Muncan, Vanesa
|b 11
700 1 _ |a Elbers, Clara C
|b 12
700 1 _ |a Lenos, Kristiaan J
|b 13
700 1 _ |a Zwijnenburg, Danny A
|b 14
700 1 _ |a van Eijndhoven, Monique A J
|b 15
700 1 _ |a Pegtel, Dirk Michiel
|b 16
700 1 _ |a van Neerven, Sanne M
|b 17
700 1 _ |a Loayza-Puch, Fabricio
|0 P:(DE-He78)4af0380446b05b5f1995502016151a1b
|b 18
700 1 _ |a Dadali, Tulin
|b 19
700 1 _ |a Broom, Wendy J
|b 20
700 1 _ |a Maier, Martin A
|b 21
700 1 _ |a Koster, Jan
|b 22
700 1 _ |a Vermeulen, Louis
|0 0000-0002-3253-2971
|b 23
700 1 _ |a Léveillé, Nicolas
|0 0000-0002-6086-5984
|b 24
773 _ _ |a 10.1136/gutjnl-2024-332752
|g p. gutjnl-2024-332752 -
|0 PERI:(DE-600)1492637-4
|n 4
|p 571-585
|t Gut
|v 74
|y 2025
|x 0017-5749
909 C O |p VDB
|o oai:inrepo02.dkfz.de:294580
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)dc4f734225935c3650fde7619c82ed92
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 18
|6 P:(DE-He78)4af0380446b05b5f1995502016151a1b
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2024
915 _ _ |a National-Konsortium
|0 StatID:(DE-HGF)0430
|2 StatID
|d 2023-10-21
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b GUT : 2022
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-21
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-21
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-21
915 _ _ |a IF >= 20
|0 StatID:(DE-HGF)9920
|2 StatID
|b GUT : 2022
|d 2023-10-21
920 1 _ |0 I:(DE-He78)B250-20160331
|k B250
|l B250 NWG Translationskontrolle und Stoffwechsel
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B250-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21